000 01824 a2200517 4500
005 20250516225529.0
264 0 _c20150728
008 201507s 0 0 eng d
022 _a2567-689X
024 7 _a10.1160/TH13-06-0469
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSchürmann, Daniel
245 0 0 _aC1-esterase inhibitor treatment: preclinical safety aspects on the potential prothrombotic risk.
_h[electronic resource]
260 _bThrombosis and haemostasis
_cNov 2014
300 _a960-71 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aArterial Occlusive Diseases
_xchemically induced
650 0 4 _aBlood Coagulation Tests
650 0 4 _aComplement C1 Inhibitor Protein
_xadministration & dosage
650 0 4 _aDisease Models, Animal
650 0 4 _aDose-Response Relationship, Drug
650 0 4 _aDrug Evaluation, Preclinical
650 0 4 _aFactor XIIa
_xanalysis
650 0 4 _aFactor XIa
_xanalysis
650 0 4 _aFemoral Artery
650 0 4 _aFibrinolysis
_xdrug effects
650 0 4 _aHumans
650 0 4 _aInfusions, Intravenous
650 0 4 _aKallikrein-Kinin System
_xdrug effects
650 0 4 _aPlatelet Aggregation
_xdrug effects
650 0 4 _aRabbits
650 0 4 _aThrombelastography
650 0 4 _aThrombin
_xbiosynthesis
650 0 4 _aVenous Thrombosis
_xchemically induced
700 1 _aHerzog, Eva
700 1 _aRaquet, Elmar
700 1 _aNolte, Marc W
700 1 _aMay, Frauke
700 1 _aMüller-Cohrs, Jochen
700 1 _aBjörkqvist, Jenny
700 1 _aDickneite, Gerhard
700 1 _aPragst, Ingo
773 0 _tThrombosis and haemostasis
_gvol. 112
_gno. 5
_gp. 960-71
856 4 0 _uhttps://doi.org/10.1160/TH13-06-0469
_zAvailable from publisher's website
999 _c24080296
_d24080296